Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer

E. Ferrari, D. A. Maffeo, R. Graziano, M. S. Gallo, S. Pignata, L. De Rosa, M. Montella, M. Pergola

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-five patients with Stage III ovarian cancer were entered into a trial with intraperitoneal combinations of carboplatin (400 mg/cqm) and recombinant interferon alfa (50 MU). All patients had received prior intravenous platinum-based chemotherapy and underwent 2nd look laparotomy at study entry. Our study indicates that this combination chemotherapy is safely administered by the intraperitoneal route. Myelotoxicity was frequent, but rarely of grade 3. No major local toxicity was recorded by accessing the peritoneal cavity with a temporary catheter. The response to treatment was promising in the group of patients with less then 2 cm residual disease at study entry (15 patients); in this group, all patients had no clinical evidence of disease at the completion of the therapy. In 2 cases reexploration was performed and pCR was recorded. Only one patient of this group relapsed during a mean follow-up of 21 months. Two pCRS were also recorded in the group of patients with more than 2 cm at 2nd look (9 patients) although relapse occurred after 9 and 15 months respectively. In the remaining patients of this group, persistence of disease was observed after intraperitoneal chemotherapy.

Original languageEnglish
Pages (from-to)437-442
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume15
Issue number6
Publication statusPublished - 1994

Fingerprint

Carboplatin
Interferon-alpha
Ovarian Neoplasms
Drug Therapy
Peritoneal Cavity
Combination Drug Therapy
Platinum
Laparotomy
Catheters
Recurrence
Therapeutics

Keywords

  • Chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Ferrari, E., Maffeo, D. A., Graziano, R., Gallo, M. S., Pignata, S., De Rosa, L., ... Pergola, M. (1994). Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. European Journal of Gynaecological Oncology, 15(6), 437-442.

Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. / Ferrari, E.; Maffeo, D. A.; Graziano, R.; Gallo, M. S.; Pignata, S.; De Rosa, L.; Montella, M.; Pergola, M.

In: European Journal of Gynaecological Oncology, Vol. 15, No. 6, 1994, p. 437-442.

Research output: Contribution to journalArticle

Ferrari, E, Maffeo, DA, Graziano, R, Gallo, MS, Pignata, S, De Rosa, L, Montella, M & Pergola, M 1994, 'Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer', European Journal of Gynaecological Oncology, vol. 15, no. 6, pp. 437-442.
Ferrari, E. ; Maffeo, D. A. ; Graziano, R. ; Gallo, M. S. ; Pignata, S. ; De Rosa, L. ; Montella, M. ; Pergola, M. / Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. In: European Journal of Gynaecological Oncology. 1994 ; Vol. 15, No. 6. pp. 437-442.
@article{e9901296c8654398bf527e4ab2d7a97e,
title = "Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer",
abstract = "Twenty-five patients with Stage III ovarian cancer were entered into a trial with intraperitoneal combinations of carboplatin (400 mg/cqm) and recombinant interferon alfa (50 MU). All patients had received prior intravenous platinum-based chemotherapy and underwent 2nd look laparotomy at study entry. Our study indicates that this combination chemotherapy is safely administered by the intraperitoneal route. Myelotoxicity was frequent, but rarely of grade 3. No major local toxicity was recorded by accessing the peritoneal cavity with a temporary catheter. The response to treatment was promising in the group of patients with less then 2 cm residual disease at study entry (15 patients); in this group, all patients had no clinical evidence of disease at the completion of the therapy. In 2 cases reexploration was performed and pCR was recorded. Only one patient of this group relapsed during a mean follow-up of 21 months. Two pCRS were also recorded in the group of patients with more than 2 cm at 2nd look (9 patients) although relapse occurred after 9 and 15 months respectively. In the remaining patients of this group, persistence of disease was observed after intraperitoneal chemotherapy.",
keywords = "Chemotherapy, Ovarian cancer",
author = "E. Ferrari and Maffeo, {D. A.} and R. Graziano and Gallo, {M. S.} and S. Pignata and {De Rosa}, L. and M. Montella and M. Pergola",
year = "1994",
language = "English",
volume = "15",
pages = "437--442",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "6",

}

TY - JOUR

T1 - Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer

AU - Ferrari, E.

AU - Maffeo, D. A.

AU - Graziano, R.

AU - Gallo, M. S.

AU - Pignata, S.

AU - De Rosa, L.

AU - Montella, M.

AU - Pergola, M.

PY - 1994

Y1 - 1994

N2 - Twenty-five patients with Stage III ovarian cancer were entered into a trial with intraperitoneal combinations of carboplatin (400 mg/cqm) and recombinant interferon alfa (50 MU). All patients had received prior intravenous platinum-based chemotherapy and underwent 2nd look laparotomy at study entry. Our study indicates that this combination chemotherapy is safely administered by the intraperitoneal route. Myelotoxicity was frequent, but rarely of grade 3. No major local toxicity was recorded by accessing the peritoneal cavity with a temporary catheter. The response to treatment was promising in the group of patients with less then 2 cm residual disease at study entry (15 patients); in this group, all patients had no clinical evidence of disease at the completion of the therapy. In 2 cases reexploration was performed and pCR was recorded. Only one patient of this group relapsed during a mean follow-up of 21 months. Two pCRS were also recorded in the group of patients with more than 2 cm at 2nd look (9 patients) although relapse occurred after 9 and 15 months respectively. In the remaining patients of this group, persistence of disease was observed after intraperitoneal chemotherapy.

AB - Twenty-five patients with Stage III ovarian cancer were entered into a trial with intraperitoneal combinations of carboplatin (400 mg/cqm) and recombinant interferon alfa (50 MU). All patients had received prior intravenous platinum-based chemotherapy and underwent 2nd look laparotomy at study entry. Our study indicates that this combination chemotherapy is safely administered by the intraperitoneal route. Myelotoxicity was frequent, but rarely of grade 3. No major local toxicity was recorded by accessing the peritoneal cavity with a temporary catheter. The response to treatment was promising in the group of patients with less then 2 cm residual disease at study entry (15 patients); in this group, all patients had no clinical evidence of disease at the completion of the therapy. In 2 cases reexploration was performed and pCR was recorded. Only one patient of this group relapsed during a mean follow-up of 21 months. Two pCRS were also recorded in the group of patients with more than 2 cm at 2nd look (9 patients) although relapse occurred after 9 and 15 months respectively. In the remaining patients of this group, persistence of disease was observed after intraperitoneal chemotherapy.

KW - Chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0028117875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028117875&partnerID=8YFLogxK

M3 - Article

C2 - 7875158

AN - SCOPUS:0028117875

VL - 15

SP - 437

EP - 442

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 6

ER -